How will the new GDP guidance affect the clinical supply chain?
In particular how will it affect the non IMP supply chain?
These guidelines outlined significant changes within the areas of general pharmaceutical storage and product distribution for all wholesale & distribution activities including clinical trial supply. Due to the importance of integrated supply chain management, these guidelines cannot be overlooked.
This whitepaper will walk you through the differences between the old guidelines and the new, emphasising the key points and expanding on what this will mean for your business.
And remember to keep an eye out for our forthcoming webinar on this topic!
You may also like:
An Interview with Dan Bell - Clinical Trial Supply Europe